Description du projet
Traitement à base de galectine-3 pour la fibrose pulmonaire
La fibrose pulmonaire se caractérise par la cicatrisation et l’épaississement du tissu pulmonaire. La fibrose pulmonaire idiopathique (FPI) est le type le plus courant de maladie pulmonaire interstitielle qui affecte les tissus conjonctifs du poumon et des alvéoles. Compte tenu de son taux de mortalité extrêmement élevé et de l’absence de traitement, il est urgent d’étudier les mécanismes pathologiques pour permettre le développement d’un traitement. Le projet Pulmonary Fibrosis, financé par l’UE, s’appuiera sur l’effet prometteur de la galectine-3 dans le ralentissement de la progression de la FPI. Le projet entend optimiser la nébulisation d’un nouveau médicament inhibiteur de la galectine-3 (TD139) sous forme d’hydrogel en utilisant le modèle préclinique induit par la bléomycine. L’étude est assortie d’une analyse génomique des trajectoires de l’ARN unicellulaire et des schémas de glycosylation des tissus pour établir une corrélation avec la maladie.
Objectif
Idiopathic Pulmonary Fibrosis (IPF) accounts for a progressive pathology with extremely high mortality and no cure available. There is a need to study pathology mechanisms for efficient treatments development. Galectin-3 (Gal-3) has shown promising effects in slowing down IPF. In this project, I will optimise nebulisation of a novel Gal-3 inhibitory drug (TD139) hydrogel treatment in bleomycin-induced PF mice model, perform an exhaustive genomic analysis to assess single-cell RNA trajectories during pathology recovery, and analyse tissue glycosylation patters for disease correlation. All this will allow for information on diseases and healing mechanisms to development efficient biomaterials treatments and contribute to the 3rd Sustainable Development Goal of the United Nations “Good Health and Well-Being” for all. I will perform nebulisation studies during secondment in specialised aerosol drug delivery industry (Aerogen®/John Power) (Ireland), in vivo model and exhaustive genomic analysis during outgoing phase in IPF genomic expert lab (Prof Kaminski) at PCCSM, Yale School of Medicine (US), and thorough lectin microarray analysis during incoming phase in glycolbiologist and biomaterials expert lab (Prof Pandit) at CÚRAM, NUI Galway (Ireland). The high expertise of the supervisors, my expertise in biomaterials, the highly qualified and prestigious hosts infrastructures and the intersectoral, international and interdisciplinary aspects of the action will promote my skills for eligibility for the EU Research Council Starting Grant. This will allow me to stablish a Biomaterial Therapies Critical Mass for Respiratory Diseases (RD) in EU and comply with the EU Respiratory Society objective to promote scientific excellence to alleviate suffering of RD. In addition, I will work in a detailed career development plan to promote translation, research integrity, inclusion of minorities, audience engagement and gender dimension for a more impactful and representative research.
Champ scientifique
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
H91 Galway
Irlande